- Home
- EXTR vs CNTA Comparison
EXTR vs CNTA Comparison
Compare EXTR & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXTR
- CNTA
- Stock Information
- Founded
- EXTR 1996
- CNTA 2020
- Country
- EXTR United States
- CNTA United Kingdom
- Employees
- EXTR N/A
- CNTA N/A
- Industry
- EXTR Telecommunications Equipment
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- EXTR Telecommunications
- CNTA Health Care
- Exchange
- EXTR Nasdaq
- CNTA Nasdaq
- Market Cap
- EXTR 2.6B
- CNTA 2.3B
- IPO Year
- EXTR 1999
- CNTA 2021
- Fundamental
- Price
- EXTR $20.67
- CNTA $17.01
- Analyst Decision
- EXTR Strong Buy
- CNTA Strong Buy
- Analyst Count
- EXTR 6
- CNTA 10
- Target Price
- EXTR $21.42
- CNTA $30.56
- AVG Volume (30 Days)
- EXTR 1.4M
- CNTA 1.2M
- Earning Date
- EXTR 08-06-2025
- CNTA 08-12-2025
- Dividend Yield
- EXTR N/A
- CNTA N/A
- EPS Growth
- EXTR N/A
- CNTA N/A
- EPS
- EXTR N/A
- CNTA N/A
- Revenue
- EXTR $1,140,067,000.00
- CNTA $15,000,000.00
- Revenue This Year
- EXTR $10.26
- CNTA N/A
- Revenue Next Year
- EXTR $7.48
- CNTA N/A
- P/E Ratio
- EXTR N/A
- CNTA N/A
- Revenue Growth
- EXTR 2.05
- CNTA 118.88
- 52 Week Low
- EXTR $10.10
- CNTA $9.60
- 52 Week High
- EXTR $21.35
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- EXTR 67.59
- CNTA 54.91
- Support Level
- EXTR $19.43
- CNTA $17.01
- Resistance Level
- EXTR $20.29
- CNTA $18.14
- Average True Range (ATR)
- EXTR 0.84
- CNTA 0.81
- MACD
- EXTR 0.02
- CNTA -0.10
- Stochastic Oscillator
- EXTR 82.65
- CNTA 51.08
About EXTR Extreme Networks Inc.
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.